ArticleEuropean heart journal2022
Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality.
Article in European heart journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 4 syntheses or guidelines pooled it, 190 citations in OpenAlex.
- BNP and NT-proBNP as prognostic biomarkers for the prediction of adverse outcomes in HFpEF patients: A systematic review and meta-analysis.Heart failure reviews · 2025Pooled it
- Systematic review and meta-analysis to predict mortality in heart failure with preserved ejection fraction: Development and validation of the HF-DANAS score.ESC heart failure · 2024Pooled it
- Heart failure with preserved ejection fraction management: a systematic review of clinical practice guidelines and recommendations.European heart journal. Quality of care & clinical outcomes · 2024Pooled it
- Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Heart Failure With Preserved Ejection Fraction and Lower Natriuretic Peptide: Clinical Characteristics and Change in Natriuretic Peptide Levels.Journal of the American Heart Association · 2025Trial
- Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.Circulation · 2025 · on this mapTrial
- The natriuretic peptide blind spot in obesity-related heart failure with preserved ejection fraction.Annals of medicine and surgery (2012) · 2026Article
- Candidate Residual Inflammatory Risk in HFpEF: A Multiorgan Framework for Longitudinal Phenotyping, Trial Enrichment, and Therapeutic Evidence Appraisal.Cardiovascular drugs and therapy · 2026Review
- Ketogenic diet and ketone salts differentially improve cardiometabolic complications in an HFpEF rat model.The Journal of physiology · 2026Article
- HFpEF and MASLD: converging mechanisms and clinical implications.Nature reviews. Cardiology · 2026Review
- Left ventricular chamber stiffness and strain determines the myocardial transcriptional response to elevated filling pressure.American journal of physiology. Heart and circulatory physiology · 2026Article
- Heart Failure With Mildly Reduced Ejection Fraction: A Heart Failure Society of America Scientific Statement.Journal of cardiac failure · 2026Review
- Obesity and Heart Failure: Introducing the Theme.Journal of cardiovascular development and disease · 2026Review
- Influence of Phenotypes on Short-Term Outcomes in Hospitalized Heart Failure with Preserved Ejection Fraction-Insights from a North-Eastern Romanian Cohort.Medical sciences (Basel, Switzerland) · 2026Article
- Biomarkers for Screening and Diagnosis of Heart Failure in Cardiovascular-Kidney-Metabolic Syndrome: A Narrative Review.International journal of molecular sciences · 2026Review
- Efficacy and safety of Shengxian Yixin Granule for treating heart failure with preserved ejection fraction: a study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.Frontiers in cardiovascular medicine · 2026Article
- Application ofAmerican journal of translational research · 2026Article
- NT-proBNP-echocardiographic discordance in type 2 diabetes: links with adiposity and left atrioventricular coupling.Frontiers in endocrinology · 2026Article
- Novel blood biomarkers for heart failure mortality: mechanistic pathways, aging biology, and risk stratification.Frontiers in cardiovascular medicine · 2026Review
- Relationship of Cardiopulmonary Exercise Capacity to Coronary Microvascular Function and Body Composition in Patients with Suspected Heart Failure with Preserved Ejection Fraction.Cardiac failure review · 2026Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundA substantial proportion of patients with heart failure (HF) with preserved ejection fraction (HFpEF) present with normal natriuretic peptide (NP) levels. The pathophysiology and natural history for this phenotype remain unclear. METHODS AND
resultsConsecutive subjects undergoing invasive cardiopulmonary exercise testing for unexplained dyspnoea at Mayo Clinic in 2006-18 were studied. Heart failure with preserved ejection fraction was defined as a pulmonary arterial wedge pressure (PAWP) ≥15 mmHg (rest) or ≥25 mmHg (exercise). Patients with HFpEF and normal NP [N-terminal of the pro-hormone B-type natriuretic peptide (NT-proBNP) < 125 ng/L] were compared with HFpEF with high NP (NT-proBNP ≥ 125 ng/L) and controls with normal haemodynamics. Patients with HFpEF and normal (n = 157) vs. high NP (n = 263) were younger, yet older than controls (n = 161), with an intermediate comorbidity profile. Normal NP HFpEF was associated with more left ventricular hypertrophy and worse diastolic function compared with controls, but better diastolic function, lower left atrial volumes, superior right ventricular function, and less mitral/tricuspid regurgitation compared with high NP HFpEF. Cardiac output (CO) reserve with exercise was preserved in normal NP HFpEF [101% predicted, interquartile range (IQR): 75-124%], but this was achieved only at the cost of higher left ventricular transmural pressure (LVTMP) (14 ± 6 mmHg vs. 7 ± 4 mmHg in controls, P < 0.001). In contrast, CO reserve was decreased in high NP HFpEF (85% predicted, IQR: 59-109%), with lower LVTMP (10 ± 8 mmHg) compared with normal NP HFpEF (P < 0.001), despite similar PAWP. Patients with high NP HFpEF displayed the highest event rates, but normal NP HFpEF still had 2.7-fold higher risk for mortality or HF readmissions compared with controls (hazard ratio: 2.74, 95% confidence interval: 1.02-7.32) after adjusting for age, sex, and body mass index.
conclusionPatients with HFpEF and normal NP display mild diastolic dysfunction and preserved CO reserve during exercise, despite marked elevation in filling pressures. While clinical outcomes are not as poor compared with patients with high NP, patients with normal NP HFpEF exhibit increased risk of death or HF readmissions compared with patients without HF, emphasizing the importance of this phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.